Tailored Antibacterials and Innovative Laboratories for Phage (Φ) Research: Personalized Infectious Disease Medicine for the Most Vulnerable At-Risk Patients.

Autor:	Terwilliger AL; Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA., Gu Liu C; Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA., Green SI; Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA., Clark JR; Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA., Salazar KC; Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA., Hernandez Santos H; Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA., Heckmann ER; Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA., Trautner BW; Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA.; Center for Innovations in Quality, Effectiveness and Safety (IQuESt), Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, USA.; Section of Health Services Research, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA., Ramig RF; Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA., Maresso AW; Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA.
Jazyk:	angličtina
Zdroj:	PHAGE (New Rochelle, N.Y.) [Phage (New Rochelle)] 2020 Jun 01; Vol. 1 (2), pp. 66-74. Date of Electronic Publication: 2020 Jun 16.
DOI:	10.1089/phage.2020.0007
Abstrakt:	Mutation is the most powerful driver of change for life on Earth. Pathogenic bacteria utilize mutation as a means to survive strong live-die selective pressures generated by chemical antibiotics. As such, the traditional drug-making pipeline, characterized by significant financial and time investment, is insufficient to keep pace with the rapid evolution of bacterial resistance to structurally fixed and chemically unmalleable antibacterial compounds. In contrast, the genetic diversity and adaptive mutability of the bacteriophage can be leveraged to not only overcome resistance but also used for the development of enhanced traits that increase lytic potential and therapeutic efficacy in relevant host microenvironments. This is the fundamental premise behind Baylor College of Medicine's Tailored Antibacterials and Innovative Laboratories for Phage (Φ) Research (TAILΦR) initiative. In this perspective, we outline the concept, structure, and process behind TAILΦR's attempt to generate a personalized therapeutic phage that addresses the most clinically challenging of bacterial infections. Competing Interests: No competing financial interests exist. (Copyright 2020, Mary Ann Liebert, Inc., publishers.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu